Crelux GmbH

Crelux GmbH is a Germany-based company specializing in advanced solutions for drug discovery, focusing on high-quality proteins and integrated services in structural biology and medicinal chemistry. Crelux GmbH, founded in 2005, operates in the field of drug discovery with a specialization in providing high-quality proteins and various analytical services. In April 2016, the company was acquired by Wuxi PharmaTech Co. , Ltd, a significant move that solidified its position in the pharmaceutical sector.

The company is headquartered in Germany, further underscoring its European operational base. Crelux specializes in providing a comprehensive suite of solutions tailored for drug discovery, focusing on high-quality CRELUX PROTEIN and integrated services in protein science, structural biology, biophysical and biochemical analysis, library screening, and medicinal chemistry. The company's core offerings include off-the-shelf and gene-to-structure services, as well as fragment screening and hit identification technologies, designed to expedite early stages of drug development. These services support clients across various pharmaceutical sectors, including small and large molecule therapies and biopharmaceuticals, facilitating target validation, fast hit finding, and lead series optimization.

Crelux caters to a global clientele, including research institutions and pharmaceutical companies, primarily in North America, Europe, and parts of Asia, thereby providing a wide geographical reach in the healthcare sector. In 2022, Crelux reported a revenue of USD 16. 57 mn and an EBITDA of USD 2. 26 mn for the most recent year, reflecting its structured transaction model that includes partnerships and collaborations with pharmaceutical and biotechnology companies.

The company's revenue model is based on project-based contracts and retainers for services such as X-ray crystallography, cryo-electron microscopy, and medicinal chemistry consulting, ensuring tailored solutions to meet clients' diverse requirements. Crelux GmbH is focused on enhancing its product offerings and expanding its market reach. Recent initiatives include the development of new analytical technologies and services to support drug discovery. The company aims to expand into North American and Asian markets by 2025, leveraging the recent acquisition's resources and strategic direction.

Following the acquisition by Wuxi PharmaTech Co. , Ltd in April 2016, Crelux is positioned to utilize the backing of its parent company to explore new projects and collaborations, enhancing its service offerings in alignment with emerging market needs.